Mito Target is a resource for ALS information and research

The Project

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS). The links between mitochondrial dysfunction and the onset and progress of some of these diseases, however, still needs to be explained in more detail. In diseases where this link is already established, the question remains whether drugs developed with regard to specific targets or mechanisms involved in mitochondrial dysfunction can affect the diseases in question. Read more about the project

Latest News

Actelion joins forces with Trophos to further advance olesoxime to the market once results of the MitoTarget clinical study are known.

20 July 2010

Actelion obtains option to acquire privately-held Trophos Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be furth

Trophos completes patients enrolment in ALS trial

17 March 2010

Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) Topline results of the study are expected 4th quarter 20